H.I.G. Growth Partners invests in Carebox to scale AI clinical-trial matching

What's the deal? H.I.G. Growth PartnersDealroom has a profile for this one. Try Dealroom →, the growth capital arm of H.I.G. Capital, has made a significant equity investment in CareboxDealroom has a profile for this one. Try Dealroom →, a software platform that connects patients with clinical trials. The exact deal size was not disclosed.

Carebox works with more than 40 life science firms, research organisations, and foundations. Its AI-powered platform, CareboxConnect, assesses patient eligibility for clinical trials based on condition, treatment history, and genomic data. More than two million users have engaged with the platform.

"No patient should miss an available treatment option or clinical trial due to a lack of awareness," said Brian WeissDealroom has a profile for this one. Try Dealroom →, founder and chief executive officer of Carebox.

H.I.G. Capital manages about $66 billion in assets across healthcare, technology, and financial services.

Why now? Clinical trial recruitment remains one of the biggest bottlenecks in drug development — an industry worth an estimated $100 billion. Matching patients to the right trials is still slow and fragmented, and AI tools are now mature enough to automate eligibility screening at scale.

For Carebox, the timing aligns with growing demand from pharma companies to accelerate enrolment and from patients seeking faster access to experimental treatments.

What could go wrong? AI-driven patient matching raises questions about data privacy, algorithmic accuracy, and liability if patients are incorrectly matched — or missed. Regulatory scrutiny of health data platforms is intensifying on both sides of the Atlantic.

Competition is also intensifying. Several startups and large tech firms are building similar clinical trial matching tools, which could compress margins and make differentiation harder.

The signal: This deal reflects two converging trends: growth capital flowing into healthtech platforms that sit between patients and pharma, and AI becoming the default infrastructure for clinical operations. As drug development costs climb, any tool that can shorten trial timelines or widen patient pools becomes strategically valuable — and investable.

Read more: investorshangout.com